Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Joanna Jońska‐Gmyrek"'
Autor:
Joanna Jonska-Gmyrek, Piotr Peczkowski, Wojciech Michalski, Grazyna Poniatowska, Agnieszka Zolciak-Siwinska, Beata Kotowicz, Pawel Wiechno, Magdalena Golawska, Maria Kowalska, Tomasz Demkow
Publikováno v:
Contemporary Oncology, Vol 21, Iss 3, Pp 203-208 (2017)
Testicular germ cell tumours (GCT) represent about 1–2% of malignant in men. The essential therapeutic option for early-stage GCT is radical orchiectomy (RO), except in situ ations that require immediate chemotherapy in patients with a massive diss
Externí odkaz:
https://doaj.org/article/ff0de334b9da40ee8d065ecfdac5410b
Autor:
Beata Kotowicz, Malgorzata Fuksiewicz, Joanna Jonska-Gmyrek, Alicja Berezowska, Jakub Radziszewski, Mariusz Bidzinski, Maria Kowalska
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0184576 (2017)
The study aimed to assess the usefulness of the determination of cytokines: IL-8, VEGF and its soluble receptors: VEGF-R1, VEGF-R2 in patients with endometrial cancer (EC).The study group consisted of 118 patients with EC subjected to surgical treatm
Externí odkaz:
https://doaj.org/article/33be8ece83b542429145dd10fad94473
Autor:
Wojciech Michalski, Grażyna Poniatowska, Joanna Jońska‐Gmyrek, Agnieszka Żółciak‐Siwińska, Inga Zastawna, Artur Lemiński, Anna Macios, Michał Jakubczyk, Tomasz Demkow, Paweł Wiechno
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18542-18556 (2023)
Abstract Background Germ cell tumours (GCT) are highly curable malignancies. Venous thromboembolism (VTE) is a serious complication, needing better risk assessment models (RAM). Aim Identification of VTE incidence and risk factors in metastatic GCT p
Externí odkaz:
https://doaj.org/article/dcf7d1c2f35446f98f1dad25e1951019
Publikováno v:
Applied Sciences, Vol 14, Iss 16, p 7287 (2024)
Deep Inspiratory Breath Hold (DIBH) has become a valuable technique in left-breast cancer radiotherapy, offering the possibility to reduce radiation exposure to organs at risks (OARs) and minimize the risk of cardiac complications. This treatment met
Externí odkaz:
https://doaj.org/article/911d2d3edf7a471c86c891a570afdfe0
Publikováno v:
Ginekologia polska. 85(10)
Ovarian cancer has the highest mortality rate among the female genital malignancies. Its incidence is steadily increasing worldwide, especially in highly industrialized countries. Scarce and non-specific clinical symptoms in the early stages, and lac
Autor:
Joanna, Jońska-Gmyrek, Agnieszka, Zółciak-Siwińska, Leszek, Gmyrek, Jagna, Staniaszek, Bogusław, Lindner, Jolanta, Andrzejuk
Publikováno v:
Ginekologia polska. 83(8)
The impact of the tumor size on treatment outcomes in cervical cancer patients remains a subject of controversyThe assessment of prognostic value of pretreatment tumor size in cervical cancer patients.Patients of Maria Sklodowska - Curie Memorial Can
Publikováno v:
Ginekologia polska. 83(7)
Cervical cancer is a malignancy associated with high morbidity and mortality in Poland. In a high number of cases the disease is diagnosed at an advanced stage, namely FIGO IB2-IVA. The standard method for radical treatment in these patients is exter
Publikováno v:
Ginekologia polska. 82(9)
Treatment of the cervical cancer patients, especially young women, is a very important clinical problem. This is related to the standard treatment methods, used in this malignancy and the treatment complications. In most patients, the oncological tre
Autor:
Joanna, Jońska-Gmyrek, Leszek, Gmyrek, Bogusław, Lindner, Ryszard, Krynicki, Jagna, Staniaszek, Mariusz, Bidziński, Agnieszka, Zółciak-Siwińska, Krzysztof, Bujko
Publikováno v:
Ginekologia polska. 81(9)
Cervical cancer is the sixth cause of cancer morbidity and the seventh cause of cancer death among women in Poland. The rising tendency of cervical adenocarcinoma morbidity and the decrease of cervical squamous cell carcinoma have been observed. Many
Autor:
Mariusz, Bidziński, Anna, Dańska-Bidzińska, Paweł, Derlatka, Piotr, Sobiczewski, Leszek, Gmyrek, Joanna, Jońska-Gmyrek, Grzegorz, Panek
Publikováno v:
Ginekologia polska. 78(6)
The risk of endometrial cancer recurrence is estimated to be about 20%. In most cases, such situations are recognized in the first 3 years after the primary treatment. Early detection of such episodes leads to effective treatment. The aim of this stu